Diagnosis and Management of Paget’s disease of Bone in Adults: A clinical guideline

Ralston, Stuart H, Corral-Gudino, Luis, Cooper, Cyrus, Francis, Roger M, Fraser, William D, Gennari, Luigi, Guanabens, Nuria, Javaid, M Kassim, Layfield, Robert, O’Neill, Terence W, Russell, R Graham G, Stone, Michael D, Simpson, Keith, Wilkinson, Diana, Wills, Ruth, Zillikens, M. Carola and Tuck, Stephen P (2019) Diagnosis and Management of Paget’s disease of Bone in Adults: A clinical guideline. Journal of Bone and Mineral Research. ISSN 0884-0431

[img] PDF (Supplementary material) - Submitted Version
Restricted to Repository staff only until 31 December 2099.

Download (744kB) | Request a copy
    [img] PDF (Accepted manuscript) - Submitted Version
    Restricted to Repository staff only until 31 December 2099.

    Download (1311kB) | Request a copy
      [img]
      Preview
      PDF (Ralston_et_al-2019-Journal_of_Bone_and_Mineral_Research) - Published Version
      Available under License Creative Commons Attribution.

      Download (1580kB) | Preview

        Abstract

        An evidence‐based clinical guideline for the diagnosis and management of Paget's disease of bone (PDB) was developed using GRADE methodology, by a Guideline Development Group (GDG) led by the Paget's Association (UK). A systematic review of diagnostic tests and pharmacological and nonpharmacological treatment options was conducted that sought to address several key questions of clinical relevance. Twelve recommendations and five conditional recommendations were made, but there was insufficient evidence to address eight of the questions posed. The following recommendations were identified as the most important: 1) Radionuclide bone scans, in addition to targeted radiographs, are recommended as a means of fully and accurately defining the extent of metabolically active disease in patients with PDB. 2) Serum total alkaline phosphatase (ALP) is recommended as a first‐line biochemical screening test in combination with liver function tests in screening for the presence of metabolically active PDB. 3) Bisphosphonates are recommended for the treatment of bone pain associated with PDB. Zoledronic acid is recommended as the bisphosphonate most likely to give a favorable pain response. 4) Treatment aimed at improving symptoms is recommended over a treat‐to‐target strategy aimed at normalizing total ALP in PDB. 5) Total hip or knee replacements are recommended for patients with PDB who develop osteoarthritis in whom medical treatment is inadequate. There is insufficient information to recommend one type of surgical approach over another. The guideline was endorsed by the European Calcified Tissues Society, the International Osteoporosis Foundation, the American Society of Bone and Mineral Research, the Bone Research Society (UK), and the British Geriatric Society. The GDG noted that there had been a lack of research on patient‐focused clinical outcomes in PDB and identified several areas where further research was needed. © 2019 The Authors. Journal of Bone and Mineral Research Published by Wiley Periodicals Inc.

        Item Type: Article
        Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
        Depositing User: LivePure Connector
        Date Deposited: 20 Dec 2018 15:31
        Last Modified: 09 Apr 2019 14:01
        URI: https://ueaeprints.uea.ac.uk/id/eprint/69403
        DOI: 10.1002/jbmr.3657

        Actions (login required)

        View Item